| 纯度 | >80%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRMT6 |
| Uniprot No | Q96LA8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-375aa |
| 氨基酸序列 | SQPKKRKLESGGGGEGGEGTEEEDGAEREAALERPRRTKRERDQLYYECY SDVSVHEEMIADRVRTDAYRLGILRNWAALRGKTVLDVGAGTGILSIFCA QAGARRVYAVEASAIWQQAREVVRFNGLEDRVHVLPGPVETVELPEQVDA IVSEWMGYGLLHESMLSSVLHARTKWLKEGGLLLPASAELFIAPISDQML EWRLGFWSQVKQHYGVDMSCLEGFATRCLMGHSEIVVQGLSGEDVLARPQ RFAQLELSRAGLEQELEAGVGGRFRCSCYGSAPMHGFAIWFQVTFPGGES EKPLVLSTSPFHPATHWKQALLYLNEPVQVEQDTDVSGEITLLPSRDNPR RLRVLLRYKVGDQEEKTKDFAMED |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRMT6重组蛋白的3篇文献参考，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*"PRMT6-mediated methylation of H3R2 regulates gene silencing by promoting histone H3K9 trimethylation"*
**作者**：Hyunkyung Jang et al.
**摘要**：该研究利用重组PRMT6蛋白，揭示了其通过催化组蛋白H3第2位精氨酸(H3R2)的甲基化，促进H3K9三甲基化(H3K9me3)，从而参与基因沉默和异染色质形成的分子机制。
---
2. **文献名称**：*"Structural basis of substrate methylation and inhibition of PRMT6"*
**作者**：Yue Feng et al.
**摘要**：通过X射线晶体学解析了重组PRMT6蛋白与底物S-腺苷甲硫氨酸(SAM)及抑制剂的复合物结构，阐明了PRMT6的催化机制和底物特异性，为靶向PRMT6的药物设计提供了结构基础。
---
3. **文献名称**：*"PRMT6 regulates DNA virus replication through arginine methylation of the viral processivity factor"*
**作者**：Jianjun Chen et al.
**摘要**：研究发现重组PRMT6蛋白可甲基化特定病毒DNA聚合酶持续合成因子(如HPV E2蛋白)，抑制其与DNA的结合能力，从而限制病毒复制，揭示了PRMT6在抗病毒防御中的新功能。
---
这些研究涵盖了PRMT6的酶学机制、结构生物学及病理功能，均涉及重组蛋白的表达纯化与功能分析。如需具体文献来源，建议通过PubMed或SciHub输入标题或DOI查询全文。
Protein arginine methyltransferase 6 (PRMT6) is a member of the PRMT family, a group of enzymes that catalyze the post-translational methylation of arginine residues in proteins. As a type I PRMT, PRMT6 predominantly mediates asymmetric dimethylation of arginine, playing a critical role in epigenetic regulation, chromatin remodeling, and cellular signaling. It is primarily localized in the nucleus and interacts with histones (e.g., H3R2me2a) and non-histone substrates to modulate gene expression, DNA repair, and cell cycle progression. PRMT6 is unique among PRMTs due to its auto-methylation activity and preference for specific substrate motifs.
Recombinant PRMT6 protein is engineered for in vitro studies to explore its enzymatic mechanisms, substrate specificity, and interactions. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), the recombinant form retains catalytic activity and structural features of the native enzyme, often fused with tags (e.g., His or GST) for purification and detection. Its applications include screening inhibitors for cancer therapy, studying epigenetic dysregulation in diseases, and analyzing viral-host interactions (e.g., HIV-1 replication, where PRMT6 methylates viral proteins to influence infectivity).
Research highlights PRMT6's dual roles in oncogenesis—acting as both a tumor suppressor and promoter depending on context—and its involvement in neurodevelopmental disorders. Recombinant PRMT6 thus serves as a vital tool for dissecting its biological functions and developing targeted therapies.
×
